• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines

tetano

Editor, Senior Moderator
EBioMedicine. 2016 Dec 1. pii: S2352-3964(16)30519-9. doi: 10.1016/j.ebiom.2016.11.015. [Epub ahead of print]
[h=1]Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines.[/h] Hayashi M[SUP]1[/SUP], Aoshi T[SUP]2[/SUP], Haseda Y[SUP]2[/SUP], Kobiyama K[SUP]2[/SUP], Wijaya E[SUP]3[/SUP], Nakatsu N[SUP]4[/SUP], Igarashi Y[SUP]4[/SUP], Standley DM[SUP]3[/SUP], Yamada H[SUP]4[/SUP], Honda-Okubo Y[SUP]5[/SUP], Hara H[SUP]6[/SUP], Saito T[SUP]7[/SUP], Takai T[SUP]8[/SUP], Coban C[SUP]9[/SUP], Petrovsky N[SUP]10[/SUP], Ishii KJ[SUP]11[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Advax, a delta inulin-derived microparticle, has been developed as an adjuvant for several vaccines. However, its immunological characteristics and potential mechanism of action are yet to be elucidated. Here, we show that Advax behaves as a type-2 adjuvant when combined with influenza split vaccine, a T helper (Th)2-type antigen, but behaves as a type-1 adjuvant when combined with influenza inactivated whole virion (WV), a Th1-type antigen. In addition, an adjuvant effect was not observed when Advax-adjuvanted WV vaccine was used to immunize toll-like receptor (TLR) 7 knockout mice which are unable to respond to RNA contained in WV antigen. Similarly, no adjuvant effect was seen when Advax was combined with endotoxin-free ovalbumin, a neutral Th0-type antigen. An adjuvant effect was also not seen in tumor necrosis factor (TNF)-α knockout mice, and the adjuvant effect required the presences of dendritic cells (DCs) and phagocytic macrophages. Therefore, unlike other adjuvants, Advax potentiates the intrinsic or in-built adjuvant property of co-administered antigens. Hence, Advax is a unique class of adjuvant which can potentiate the intrinsic adjuvant feature of the vaccine antigens through a yet to be determined mechanism.
Copyright © 2016. Published by Elsevier B.V.


[h=4]KEYWORDS:[/h] Adjuvant; Inulin; Macrophage; Particle; Vaccine

PMID: 27919753 DOI: 10.1016/j.ebiom.2016.11.015
[PubMed - as supplied by publisher]
 
Back
Top Bottom